Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica - Italy
doi 10.3324/haematol.2019.217141
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Optimal Treatment for Chronic Active Epstein-Barr Virus Disease

Pediatric Transplantation
Child HealthTransplantationPediatricsPerinatology
2009English

Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2019English

Soluble CD30: A Serum Marker for Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Journal of Medical Virology
VirologyInfectious Diseases
2010English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

Oncologist
Cancer ResearchMedicineOncology
2005English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Characterization of Epstein-Barr Virus Genomes in Transplant Lymphoma/Lymphoproliferative Disease

Pediatric Research
Child HealthPediatricsPerinatology
1987English

Epstein-Barr Virus-Associated Γδ T-Cell Lymphoproliferative Disorder Associated With Hypomorphic IL2RG Mutation

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2019English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy